Proof-of-concept exploit code has been published for a critical remote code execution flaw in protobuf.js, a widely used ...
Rendering isn’t always immediate or complete. Learn where no-JavaScript fallbacks still protect critical content, links, and ...
Maine’s legislature has passed the nation’s first statewide moratorium on energy-hungry data centers. It's an expansion of political opposition to tech giants’ massive artificial intelligence data ...
seamless-immutable Immutable JS data structures which are backwards-compatible with normal Arrays and Objects. Use them in for loops, pass them to functions expecting vanilla JavaScript data ...
I'm an independent creator passionate about building useful tools, simulations, and theories that make complex ideas more accessible. I explore the intersection of technology, education, and human ...
Elon Musk offered a first look at his plans for orbiting data centers this weekend, and they will be longer than the International Space Station (ISS). The satellites stand out for their exceptionally ...
Nvidia has a structured data enablement strategy. Nvidia provides libaries, software and hardware to index and search data faster. The Indexing and retrievals are way faster 10-40X faster in most ...
Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral ...
Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...
Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to set their weight loss assets apart in an increasingly crowded field as ...
Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...